BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022;10:274. [DOI: 10.3390/biomedicines10020274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Moeckli B, Pham T, Slits F, Latrille S, Peloso A, Delaune V, Oldani G, Lacotte S, Toso C. FGF21 negatively affects long-term female fertility in mice. Heliyon 2022;8:e11490. [DOI: 10.1016/j.heliyon.2022.e11490] [Reference Citation Analysis]
2 Wu Q, Chen Z, Ding Y, Tang Y, Cheng Y. Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis. Front Nutr 2022;9:1033129. [DOI: 10.3389/fnut.2022.1033129] [Reference Citation Analysis]
3 Okovityi SV, Raikhelson KL, Prikhodko VA. Combined hepatoprotective pharmacotherapy for liver disease. jour 2022. [DOI: 10.31146/1682-8658-ecg-203-7-5-20] [Reference Citation Analysis]
4 Liu X, Jiang Y, Ye J, Wang X. Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease. Front Immunol 2022;13:999412. [DOI: 10.3389/fimmu.2022.999412] [Reference Citation Analysis]
5 Latif F, Saqib V, Waqar E. Dementia and non-alcoholic fatty liver disease – An unprecedented relationship. Annals of Medicine and Surgery 2022;81:104359. [DOI: 10.1016/j.amsu.2022.104359] [Reference Citation Analysis]
6 Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother 2022;154:113577. [PMID: 35988420 DOI: 10.1016/j.biopha.2022.113577] [Reference Citation Analysis]
7 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
8 Subramanian P, Hampe J, Tacke F, Chavakis T. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). IJMS 2022;23:6996. [DOI: 10.3390/ijms23136996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]